Related Experiment Videos
Augmentation of immune responses after methotrexate administration
Immunology
|February 1, 1979
Summary
Methotrexate (MTX) treatment in mice enhances spleen cell immune reactivity, boosting responses to PHA and GvH. This immune enhancement was particularly notable in BCG-treated mice, suggesting MTX-sensitive cells may suppress immune responses.
Area of Science:
- Immunology
- Pharmacology
Background:
- Methotrexate (MTX) is an immunosuppressive drug.
- The effects of MTX on immune responses can be complex and context-dependent.
Purpose of the Study:
- To investigate the impact of a single MTX injection on immune cell reactivity in mice.
- To determine if MTX can modulate immune responses in conjunction with other treatments like BCG or thymectomy.
Main Methods:
- Mice received a single intraperitoneal injection of 0.5 mg MTX.
- Spleen cell reactivity was assessed by PHA and GvH assays five days post-injection.
- Mice were also treated with BCG or underwent adult thymectomy prior to MTX administration and immune assessment.
- Specific antibody-forming cell (PFC) responses to SRBC were measured.
Main Results:
- MTX treatment increased PHA and GvH reactivity of spleen cells.
- MTX-enhanced immune responses were more pronounced in mice pre-treated with BCG.
- MTX also enhanced GvH reactivity in thymectomized mice.
- Mice treated with MTX showed increased direct PFC responses to SRBC.
Conclusions:
- A single dose of MTX can enhance immune reactivity in mice.
- MTX-mediated immune enhancement is particularly evident in the context of BCG immunotherapy.
- MTX-sensitive cells may play a suppressive role in immune responses, especially in BCG-treated mice.